In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty have reported relationships with ineligible companies:
Petros Grivas, MD, PhD, chair for this educational event, is a contracted researcher for Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics; and receives consulting fees from AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck & Co., Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, and UroGen.
Shilpa Gupta, MD, faculty for this educational event, receives consulting fees from BMS, Pfizer, Merck, Gilead, Bayer, Seattle Genetics, Signetara, Guardant, and Janssen.
Vadim S. Koshkin, MD, faculty for this educational event, is a contracted researcher for Endocyte, Nektar, Clovis Oncology, Janssen, Taiho Oncology, and Merck; and receives consulting fees from AstraZeneca, Clovis Oncology, Janssen, Pfizer, EMD Serono, Seagen, Astellas Pharma, Dendreon, Guidepoint, GLG, and ExpertConnect.